Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04866069
Recruitment Status : Recruiting
First Posted : April 29, 2021
Last Update Posted : May 6, 2021
Sponsor:
Collaborators:
The Scientific and Technological Research Council of Turkey
VETAL Inc.
MonitorCRO
Information provided by (Responsible Party):
Osman ERGANIS, PhD, Prof, The Scientific and Technological Research Council of Turkey

Brief Summary:
This phase I study is designed as double-blinded, randomised, placebo controlled, three-armed study composed of two different dose arms of protective adjuvanted inactivated vaccine against SARS-CoV-2 in dose escalations (first low dose group, followed by high dose group) and placebo arm.

Condition or disease Intervention/treatment Phase
Covid19 Biological: SARS-CoV-2 vaccine Biological: Placebo Phase 1

Detailed Description:

This phase I study is designed as double-blinded, randomised, placebo controlled, three-armed study composed of two different dose arms of protective adjuvanted inactivated vaccine against SARS-CoV-2 in dose escalations (first low dose group, followed by high dose group) and placebo arm. Each dose of vaccine will be defined as a cohort in itself, with vaccine administration to 20 participants and placebo administration to 5 participants. After completion of low-dose group, decision of switch to high-dose will be taken by the Independent Data Monitoring Committee and will continue accordingly.

In the study, 50 healthy participants of 18-45 years of age will be recruited.

All injections will be done subcutaneously.

Injections will be administered at 1 and 21 days.

The participants will be followed for 6 months and the study will be completed in 12 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: Double-blinded
Primary Purpose: Prevention
Official Title: Phase I Study Evaluating the Safety and Efficacy of the Protective Adjuvanted Inactivated Vaccine Developed Against SARS-CoV-2 in Healthy Participants, Administered as Two Injections Subcutaneously in Two Different Dosages.
Actual Study Start Date : April 25, 2021
Estimated Primary Completion Date : October 2021
Estimated Study Completion Date : April 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Low-Dose Group (Group A)
20 participants will receive 10 µg-3M inactivated virus + 1 mg Al(OH)3 + 300 µg CpGODN adjuvanted vaccine
Biological: SARS-CoV-2 vaccine
Adjuvanted inactivated vaccine

Experimental: High-Dose Group (Group B)
20 participants will receive 20 µg-6M inactivated virus + 1 mg Al(OH)3 + 300 µg CpGODN adjuvanted vaccine
Biological: SARS-CoV-2 vaccine
Adjuvanted inactivated vaccine

Placebo Comparator: Placebo Group
10 participants will receive 1 ml of 0.9% sodium chloride (NaCl)
Biological: Placebo
0.9% NaCl




Primary Outcome Measures :
  1. Acute adverse events (AEs) [ Time Frame: 24 hours ]
    Frequency of acute adverse events in all dosage groups

  2. Solicited local and systemic adverse events (AEs) [ Time Frame: 15 days ]
    Frequency of local and systemic AEs in all dosage groups

  3. Unsolicited local and systemic adverse events (AEs) [ Time Frame: 28 days ]
    Frequency of local and systemic AEs in all dosage groups


Secondary Outcome Measures :
  1. Neutralizing antibody response [ Time Frame: Before first dose administration, on Day 21-28-35 and Month 3 and Month 6 after first dose administration. ]
    Immunogenicity response by measuring neutralizing antibody titer (anti-spike and anti-RBD) developed against SARS-CoV-2 (by ELISA)

  2. Cellular immune response [ Time Frame: Before first dose administration, on Day 21-28-35 and Month 3 and Month 6 after first dose administration. ]
    Interferon-γ (IFN-γ) positive cell level (by ELISPOT)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

To be eligible for the study, each participant must satisfy all the following criteria:

  1. Healthy participants between 18-45 years of age,
  2. Sign an informed consent document,
  3. Negative immunoglobulin G (IgG) and immunoglobulin M (IgM) antibody for COVID-19,
  4. Negative quantitative polymerase chain reaction (qPCR) SARS-CoV-2 results of nasopharyngeal/sputum samples,
  5. Able to comply with the study protocol during the study period,
  6. Negative tests for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV),
  7. Body temperature <37.2 C and no signs of active infection,
  8. Body mass index 18-35 kg/m2,
  9. Normal laboratory levels of whole blood count, alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin, urea, creatinine, and fasting blood glucose, or abnormal finding detected in any laboratory parameter which is not greater than Grade 1 according to the investigator's evaluation,
  10. Good general health (no known disease in the history and physical examination within 14 days prior to the enrolment),
  11. Female and male participants who will be able to have appropriate contraception methods within 30 days prior to vaccine injection and within 6 months after vaccination,

Exclusion Criteria:

Participants with any of the following criteria will be excluded:

  1. History of seizure, encephalopathy, or psychosis,
  2. History of allergic reactions to any known vaccine or to any component of the study vaccine,
  3. Pregnant, breastfeeding, or positive pregnancy test or planning to conceive within 6 months,
  4. History of SARS-CoV-2 infection,
  5. Severe cardiovascular disorders (arrhythmia, conduction disorders, history of myocardial infarction, uncontrolled hypertension),
  6. Severe chronic disorders (asthma, diabetes mellitus, thyroid disorders…etc),
  7. Congenital or acquired angioedema,
  8. Diagnosis of immunodeficiency,
  9. Diagnosis of bleeding diathesis,
  10. Use of immunosuppressive treatment, anti-allergic treatment, cytotoxic treatment, inhaler corticosteroids (allergic rhinitis or topical steroid ointments are excluded),
  11. Those who received blood and blood product transfusions in the last 6 months,
  12. Those on any vaccine program or experimental medication within 1 month prior to the study,
  13. History of any vaccination against SARS-CoV-2 within 1 month prior to the study,
  14. Use of active tuberculosis treatment,
  15. History of addictive drug use,
  16. History of alcohol abuse and/or history of alcohol intake more than 2 units per day or 10 units per week and/or positive breath alcohol test (one unit of alcohol equals to 250 mL beer, 125 mL wine or 25 mL whiskey),
  17. According to the investigator's evaluation, those who have any condition (medical, psychological, social, etc.) that may impair the patient's compliance with the study will be excluded from the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04866069


Contacts
Layout table for location contacts
Contact: Osman ERGANIS, PhD, Prof +905324333478 erganis@selcuk.edu.tr

Locations
Layout table for location information
Turkey
Ankara City Hospital Phase I Drug Research Center Recruiting
Ankara, Turkey, 06800
Contact: Ekmel H OLCAY, MD    +905321529191    ekmelolcay@yahoo.com   
Sponsors and Collaborators
Osman ERGANIS, PhD, Prof
The Scientific and Technological Research Council of Turkey
VETAL Inc.
MonitorCRO
Layout table for additonal information
Responsible Party: Osman ERGANIS, PhD, Prof, PhD, Prof, The Scientific and Technological Research Council of Turkey
ClinicalTrials.gov Identifier: NCT04866069    
Other Study ID Numbers: ISV2AOH3ODN
First Posted: April 29, 2021    Key Record Dates
Last Update Posted: May 6, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Osman ERGANIS, PhD, Prof, The Scientific and Technological Research Council of Turkey:
SARS-CoV-2
Adjuvanted inactivated vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases